OTCM
VRAYQ
Market cap479mUSD
Nov 03, Last price
0.00
Name
ViewRay Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ViewRay, Inc. specializes in the development, production, and global distribution of advanced magnetic resonance imaging (MRI)-guided radiation therapy systems, which are utilized for both diagnosing and treating cancer patients. These systems are deployed across multiple international regions, including the United States, France, Taiwan, and the United Kingdom. The company's primary offering is MRIdian, an innovative MRI-guided radiation therapy solution specifically designed to mitigate common issues such as beam distortion and skin toxicity. ViewRay caters to a wide array of clients, ranging from academic and research hospitals to local community hospitals, private medical clinics, governmental healthcare providers, and independent cancer care facilities. The distribution of its MRIdian system is handled through a combination of a dedicated direct sales team and an extensive partner network. Established in 2004, ViewRay, Inc. has its corporate headquarters situated in Oakwood, Ohio.
Key people
Paul Ziegler
President, Chief Executive Officer · since 2023
Cassie Mahar
Interim Chief Financial Officer · since 2023
Adam Podbelski
Senior Vice President- Commercial Operations · since 2023
James Dempsey
Chief Scientific Officer · since 2020
Caley Castelein
Independent Director · since 2008
Independent Director · since 2020
Independent Chairman of the Board · since 2018
Independent Director · since 2021
Independent Director · since 2015
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||